Setmelanotide 新
仅供科学研究，不可用于个人用途。
即时询价 ×
* 必填项
请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。
Inquiry Online
×
* Required Fields.
Please complete the form below and we will contact you shortly.
Bulk Inquiry
×
* Required Fields.
Please complete the form below and we will contact you shortly.
| 中文名称 | 司美诺肽 |
| 英文名称 | Setmelanotide |
| 中文别名 | RM-493; RM493; RM 493; BIM-22493; BIM22493; BIM 22493; IRC-022493; IRC 022493; IRC022493 |
| 英文别名 | RM-493; RM493; RM 493; BIM-22493; BIM22493; BIM 22493; IRC-022493; IRC 022493; IRC022493 |
| CAS号 | 920014-72-8 |
| 产品编号 | BCP42295 |
| 纯度 | 98% |
| 分子量 | 1117.32 |
| 分子式 | C49H68N18O9S2 |
| 储存条件 | Store at 4-8°C |
| 配送 | 惯例下常温包邮（中国大陆地区） |
Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other earlier treatments for these patients included gastric bypass surgery. Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week. Imcivree was granted EMA orphan designation on 19 November 2018 and FDA approval on 25 November 2020.
Tags:Setmelanotide 供应商,Setmelanotide 购买,Setmelanotide 生产,Setmelanotide 批量,Setmelanotide 供应,Setmelanotide 订购,Setmelanotide 采购
联系方式
